<DOC>
	<DOCNO>NCT02400567</DOCNO>
	<brief_summary>The investigator propose present study innovative approach , combine recent therapeutic opportunity high risk ER+ breast cancer recent innovative diagnostic approach PAM50 signature RCB tumor response evaluation method . In line recent recommendation target anticancer therapy , investigator design parallel phase II randomize trial early stopping rule 26 , able meantime build unique prospective collection tumor tissue , pre- post-treatment .</brief_summary>
	<brief_title>Efficacy Letrozole + Palbociclib Combination Neoadjuvant Treatment Stage II-IIIA PAM 50 ROR-defined Low Intermediate Risk Luminal Breast Cancer , Postmenopausal Women</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Palbociclib</mesh_term>
	<mesh_term>Letrozole</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<mesh_term>Phenobarbital</mesh_term>
	<criteria>1 . Aged ≥ 18 year , Postmenopausal woman 2 . Newly diagnose operable unilateral invasive breast cancer , candidate uncertain breast conservation Note : Multicentric/multifocal tumor allow provide maximum 3 lesion present , share characteristic : ER Allred 4 , Her2 ( PAM50 perform large lesion ) 3 . Stage IIIIIA 4 . Assessment nodal status available ( Ultrasound guide FNA biopsy necessary ) 5 . Non metastatic , M0 6 . ERpositive IHC ( Allred Score≥4 ) 7 . HER2negative IHC ( score 0 1+ ) and/or Fish/Cish 8 . Either Luminal A AND proven nodal involvement ( cytology histology ) , Luminal B PAM50 ROR ( Prosigna™ ) centralize evaluation 9 . ECOG 01 10 . No prior systemic therapy present tumor 11 . Adequate renal , hepatic , hematopoietic function define follow criterion : Absolute Neutrophil Count ( ANC ) ≥1,500/mm3 ≥1.5 x 109/L Platelets ≥100,000/mm3 ≥100 x 109/L Hemoglobin ≥9 g/dL Serum Aspartate Transaminase ( AST ) serum Alanine Aminotransferase Transaminase ( ALT ) ≤2.5 x upper limit normal ( ULN ) Alkaline phosphatase ≤2.5 x ULN Total serum bilirubin ≤1 x ULN Serum creatinine ≤1.5 x ULN estimate creatinine clearance ≥ 60 mL/min calculate use method standard institution 12 . Adequate cardiac function , include : 12 Lead electrocardiogram ( ECG ) normal trace non clinically significant change require medical intervention . QTc interval ≤480 msec No history Torsades de Pointes symptomatic QTc abnormality . 13 . Willingness ability comply schedule visit , treatment plan , laboratory test , trial procedure 14 . Signed informed consent health insurance coverage 1 . Non operable , bilateral , T4 metastatic breast cancer 2 . Limited T2 breast cancer immediately accessible conservative surgery 3 . Previous homolateral breast cancer ( include situ carcinoma ) , and/or contralateral breast cancer except treat surgery +/ radiation therapy alone without systemic treatment 4 . Previous hormone replacement therapy ( HRT ) stop less 2 week begin treatment 5 . Previous use SERMs raloxifene 6 . Any surgery ( include minor procedure lymph node biopsy , primary tumor core biopsy , fine needle aspiration ) within 4 week start study treatment ; fully recover side effect previous procedure . 7 . Diagnosis previous malignancy within last 5 year , except adequately treat basal cell carcinoma , squamous cell skin carcinoma , situ cervical carcinoma 8 . History previous anticancer chemotherapy previous treatment use AI 9 . Concurrent administration herbal preparation complementary medicine . 10 . Any clinically significant gastrointestinal abnormality , may impair intake , transit absorption study drug , inability take oral medication tablet form malabsorption syndrome 11 . Patient psychological , familial , social geographical condition could potentially hamper compliance study protocol followup schedule ; condition discuss patient registration trial .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Luminal</keyword>
	<keyword>Post menopausal</keyword>
	<keyword>Breast conservation</keyword>
	<keyword>Neoadjuvant</keyword>
</DOC>